Fierce Pharma

SEPTEMBER 30, 2024

With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ultra-rare disease. | With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ultra-rare disease. Still, with months of prep work and outreach complete, the company is already proving it can hit the ground running.

Marketing 85

Marketing Drugs 85

Bio Pharma Dive

SEPTEMBER 30, 2024

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Medicine 293

Medicine Drugs 293

Pharmaceutical Technology

SEPTEMBER 30, 2024

The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions.

253

253

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 30, 2024

(Aja Koska/E+/Getty Images) Have you ever noticed changes in your eating habits when you are sad, bored or anxious? Many people report eating either more, or less, as a way of helping them to cope when they experience difficult emotions.

Clinical Trials 222

Clinical Trials Clinical Trials Trials 222

Advertisement

Clinical Supply

Bio Pharma Dive

SEPTEMBER 30, 2024

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

Development 157

Development Drugs 157

Rethinking Clinical Trials

SEPTEMBER 30, 2024

The NIH Pragmatic Trials Collaboratory’s Health Equity Core released a new Health Equity in Pragmatic Clinical Trials guide designed to help research teams define health equity and provide examples of how to promote it in clinical research. “Understanding what we mean by health equity is a fundamental step for integrating a health equity lens into research,” said Rosa Gonzalez-Guarda, cochair of the Health Equity Core and an associate professor and assistant dean in the Duke Un

Clinical Trials 147

Clinical Trials Clinical Trials Trials Nurses 147

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 30, 2024

Researchers see a greater need for new generation therapeutics to propel precision medicine. The development of innovative therapeutic approaches in healthcare encompass a variety of fields, including gene therapy, personalized medicine, immunotherapy, and advanced biologics.

Medicine 157

Medicine Research Gene Therapy Genetics 157

Pharmaceutical Technology

SEPTEMBER 30, 2024

Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence Awards.

Production 173

Production 173

Bio Pharma Dive

SEPTEMBER 30, 2024

Learn how optimal NGS solutions can help developers overcome challenges throughout targeted therapeutic development and the value of an end-to-end partner to help every step of the way.

Development 130

Development 130

Pharmaceutical Technology

SEPTEMBER 30, 2024

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Vaccine 173

Vaccine Vaccination 173

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Bio Pharma Dive

SEPTEMBER 30, 2024

Clinical services organizations can help pharma with global drug development and clinical trial challenges.

Clinical Trials 130

Clinical Trials Clinical Trials Marketing Trials 130

Pharmaceutical Technology

SEPTEMBER 30, 2024

LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, targeting the treatment of adult patients with plaque psoriasis.

Production 130

Production Drugs 130

pharmaphorum

SEPTEMBER 30, 2024

Find out how AI can help prevent burnout and optimise pharmacist time in the pharmacy setting. Learn how technology can streamline processes and improve efficiency in this crucial healthcare profession.

Pharmacy 106

Pharmacy 106

Pharmaceutical Technology

SEPTEMBER 30, 2024

SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small molecule and peptide production capabilities.

Production 130

Production Manufacturing Development 130

Advertisement

Clinical Supply

Fierce Pharma

SEPTEMBER 30, 2024

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. | Ahead of the CPHI conference in Milan, the events group has teased new research signaling an expected rebound for the CDMO industry—and a rejection of the BIOSECURE Act.

Research 105

Research 105

Pharmaceutical Technology

SEPTEMBER 30, 2024

The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.

147

147

Drug Discovery World

SEPTEMBER 30, 2024

Experts from Cancer Research UK Children’s Brain Tumour Centre of Excellence in Cambridge, UK are set to share around £3.2 ($4.2) million to find and test better and less toxic ways to treat children’s brain tumours. The funding announcement comes during Childhood Cancer Awareness Month. Brain tumours are the leading cause of cancer death in children and those that do survive often face life-changing side effects as a result of their treatment.

Research 103

Research Clinical Trials Clinical Trials Drugs 103

Pharmaceutical Technology

SEPTEMBER 30, 2024

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and Opdivo.

Marketing 130

Marketing 130

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

Fierce Pharma

SEPTEMBER 30, 2024

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson & Johnson and Legend Biotech’ Carvykti has once again mounted a maj | After putting on a strong performance in preventing disease progression, Johnson & Johnson and Legend Biotech’s Carvykti has once again demonstrated a major benefit—this time in prolonging patients’ lives.

99

99

Pharmaceutical Technology

SEPTEMBER 30, 2024

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in adults.

FDA Approval 130

FDA Approval Drugs 130

XTalks

SEPTEMBER 30, 2024

Promising new data from UNION Therapeutics’ ADESOS Phase IIb study show orismilast’s potential as an effective oral treatment for moderate to severe atopic dermatitis. Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, the study highlighted significant improvements in key disease markers, positioning orismilast as a potential breakthrough in atopic dermatitis management.

Clinical Trials 98

Clinical Trials Clinical Trials Dermatology Trials 98

Pharmaceutical Technology

SEPTEMBER 30, 2024

Is the pharma industry ready to realise blockchain tech’s potential in tackling counterfeit drugs?

Drugs 130

Drugs 130

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Drug Patent Watch

SEPTEMBER 30, 2024

Patent expirations have a significant impact on the pharmaceutical industry, particularly on the generic drug market. When a drug’s patent expires, other manufacturers can produce and market generic versions of the drug, leading to increased competition and lower prices.

Generic Drugs 95

Generic Drugs Marketing Drugs Manufacturing 95

Pharmaceutical Technology

SEPTEMBER 30, 2024

GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Development 100

Development Drugs 100

Pharmaceutical Commerce

SEPTEMBER 30, 2024

Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.

110

110

Pharmaceutical Technology

SEPTEMBER 30, 2024

Modalis may receive a priority review voucher if its CMD gene therapy is approved by the FDA.

Gene Therapy 130

Gene Therapy Gene 130

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

pharmaphorum

SEPTEMBER 30, 2024

Chiesi Biotech Center of Excellence opens to strengthen R&D in Italy Nicole.

111

111

Drug Discovery World

SEPTEMBER 30, 2024

Over the past 20 years, DDW has established itself as an authoritative, credible and industry leading business information platform. It makes sense then, with a close eye on industry trends and developments along with global perspective, that DDW expands its offering to include Research & Consultancy services. Through a range of surveys, in-depth interviews, primary and secondary research, round tables, events and focus groups, our consultants can provide competitive market intelligence, ind

Research 59

Research Marketing Drugs Development 59

pharmaphorum

SEPTEMBER 30, 2024

Genentech buys Regor's next-gen CDK inhibitors for $850M Jonah.

108

108

XTalks

SEPTEMBER 30, 2024

Neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Parkinson’s disease (PD) represent some of the most challenging medical conditions, with ALS, often known as Lou Gehrig’s disease, leading the way as a fatal motor neuron disorder. ALS causes the progressive degeneration of nerve cells in the brain and spinal cord, beginning with limb weakness and rapidly progressing to severe muscle atrophy, paralysis and ultimately death, often due to respiratory f

Research 59

Research Clinical Trials Clinical Trials Drugs 59

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Clinical Supply